ESMO Virtual Journal Club: January 2025

This content is for ESMO members only.

Login

Learn more about how you can join ESMO

Programme

• 22 January 2025

Welcome and introduction

Helen Gogas

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Helen Gogas

Live Q&A and Discussion

All speakers

• 

  Helen J. Gogas

  Chair

  1st Department of Internal Medicine University of Athens

Description

This ESMO Virtual Journal Club Webinar focused on two newly published studies, with an aim to enhance understanding and application of the latest research in the field.

This webinar aimed to discuss and evaluate notable recent publications on the topic of melanoma.

Christian U. Blank, Minke W. Lucas, Richard A. Scolyer et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine.

Learning objectives

• To discuss and critically evaluate notable recent publications.
• To enhance the understanding and application of the latest research in the field.
• To assess the study’s robustness, its significance to oncology practice, limitations, and its place within existing research.
• To identify and highlight any unclear aspects or unmet needs.